Trending...
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- Delta Industrial is Attending FabTech 2024 in Orlando This Fall
- VSA Officially Receives SOC 2 Approval
Working With World-Class Institutions/Collaborators to Provide Novel Treatment Approaches. Stock Symbol: GNPX
AUSTIN, Texas - Michimich -- Genprex, Inc. (Stock Symbol: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Michimich.com
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
GNPX Video: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Patent Granted in Singapore for GNPX Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
On August 13th GNPX announced that the Singapore Patent Office has granted a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.
More on Michimich.com
This GNPX patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. GNPX will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial.
$GNPX Information: www.genprex.com / https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
GNPX Media Contact: Kalyn Dabbs
Email: Media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
More on Michimich.com
- Hillside Terrace Senior Living Encourages Supporting Your Loved Ones' Emotional Well-Being
- The Giant is Coming to Las Vegas: A Landmark Blending Art, Entertainment & Blockchain for an Unforgettable Experience!
- Nurturing Healthy Smiles Through Little Mouth Program
- Experience the Future of Digital Textbook with KITABOO at FBF 2024 and Win an iPad Daily!
- Integris Composites Displays New Military Armor at AUSA 2024
New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program.
GNPX Video: https://www.genprex.com/videos/.
The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.
The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.
Patent Granted in Singapore for GNPX Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
On August 13th GNPX announced that the Singapore Patent Office has granted a patent that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies through 2037.
More on Michimich.com
- Expert HVAC Upgrade Tips to Maximize Energy Efficiency
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
This GNPX patent expands on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China and Korea to cover the use of REQORSA in combination with an immune checkpoint inhibitor, i.e., PD-1 antibodies. The granted Korean patent also claims the use of REQORSA in combination with PD-L1 antibodies. GNPX will be pursuing additional patent applications with claims to combinations of REQORSA and PD-L1 antibodies in the US, Brazil, Canada, China, Europe and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial.
$GNPX Information: www.genprex.com / https://compasslivemedia.com/gnpx/
Media Contact:
Company Name: Genprex, Inc.
GNPX Media Contact: Kalyn Dabbs
Email: Media@genprex.com
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on Michimich.com
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- OpsVeda Is Now Available Through AWS Marketplace
- Circumference Group Acquires Majority Stake in Visionary Integration Professionals
- C & C Heating & Air Conditioning says the way to combat high energy costs is with a heating tune-up
- Tim O'Loughlin Appointed Chief Executive Officer of Vantiva and Co-opted as a Director of the Board
- TN Nursery Gears Up for Busy Fall Shipping Season with Nationwide Fast Shipping, Low Grower Prices, and Storewide Deals
- Jazz Artist Bob Holz Signs With SoVibe Entertainment Plus Album Review In September 2024 Issue Of Downbeat Magazine
- Develop Africa Partners with Sierra Leonean Painter Sahr Songu Mbriwa to Raise Funds for Education
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- Plastic Fabrication Company Shares Benefits of Medical Device Plastics
- Cell-Ed and National Minority Health Association Forge Strategic Partnership to Expand Caregiving and Health Equity Initiatives
- Delta Industrial is Attending FabTech 2024 in Orlando This Fall
- Fortius Metals secures $2 Million Additional Funding to Bring Advanced Metal 3D Printing to the Aerospace and Defense Industry
- Michigan SEO Group Shares Local Marketing Strategies for Your Social Media in Ann Arbor, MI
- Voices Rising Festival Celebrates Diversity in E. Islip, GRAMMY Governor LACHI performs!
- VSA Officially Receives SOC 2 Approval
- ELKEM TO SHOWCASE ITS THERMAL MANAGEMENT MATERIALS AT THE BATTERY SHOW
- Martial Arts Icon Cynthia Rothrock Premieres Her Latest Film Black Creek
- Vantiva and Harmonic Partner to Offer Service Providers Easy Transition from DOCSIS to Fiber-based PON Technologies